TDOC - Teladoc Health, Inc.

NYSE - NYSE Delayed Price. Currency in USD
-4.70 (-4.57%)
At close: 4:02PM EST

97.85 -0.25 (-0.25%)
After hours: 7:58PM EST

Stock chart is not supported by your current browser
Previous Close102.80
Bid97.12 x 800
Ask98.37 x 900
Day's Range97.25 - 103.53
52 Week Range48.57 - 103.53
Avg. Volume1,257,672
Market Cap7.138B
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-1.47
Earnings DateOct 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est93.86
  • Teladoc Health acquiring InTouch Health
    Yahoo Finance Video

    Teladoc Health acquiring InTouch Health

    Teladoc Health CEO Jason Gorevic announces the company's $600 million deal to purchase InTouch Health, expanding its footprint in virtual healthcare.

  • Teladoc CEO on using tech to expand access to care
    Yahoo Finance Video

    Teladoc CEO on using tech to expand access to care

    Teladoc CEO Jason Gorevic joins Yahoo Finance’s Anjalee Khemlani on The First Trade to discuss the latest tech improvements and how the healthcare industry is innovating to keep up with these improvements.

  • What's in Store for HCA Healthcare's (HCA) Q4 Earnings?

    What's in Store for HCA Healthcare's (HCA) Q4 Earnings?

    HCA Healthcare's (HCA) Q4 results are likely to reflect healthy growth in revenues and admissions.

  • Investor: Health stocks a buy with Obamacare here to stay, Medicare-for-All not likely
    Yahoo Finance

    Investor: Health stocks a buy with Obamacare here to stay, Medicare-for-All not likely

    Health care stocks may be under pressure from Democratic candidates' rhetoric and Congressional scrutiny, but don't dump them yet, one analyst says.

  • Teladoc (TDOC) Hits 52-Week High: Will Momentum Sustain?

    Teladoc (TDOC) Hits 52-Week High: Will Momentum Sustain?

    Teladoc (TDOC) stock gains from from positive earnings pre-announcement and news to acquire InTouch Health.

  • Predicting Future Trends Is Hard. More Money Than Ever Is Trying

    Predicting Future Trends Is Hard. More Money Than Ever Is Trying

    (Bloomberg) -- For investors chasing “the next big thing,” there’s an oft-repeated warning: Predicting the future can lose you millions, even when you get it right.For every iPad there’s a Newton. For every Facebook there’s a MySpace.Yet as the decade begins, more cash than ever has flowed into thematic funds, which hunt for tomorrow’s winners based on today’s emerging trends. Assets under management doubled in three years to reach $175.2 billion at the end of December, according to data from Morningstar Inc.Already in 2020 there are signs the growth will continue: Lazard Asset Management launched a new offering this month, the latest addition to an increasingly crowded field currently ruled by firms including Pictet Asset Management and Nikko Asset Management’s venture with ARK Invest.Whether in electric vehicles, medical research or energy, riding macro waves of disruption is not for the faint of heart. Transformational trends don’t always look that way in the early days, while the pace of change can be punishing and unpredictable. An early Pictet bet on the first wave of clean energy was stymied by development costs. ARK Invest is currently raising eyebrows with its ultra-optimistic view of Tesla Inc.Yet these days even traditional active managers are taking on more thematic exposure within their portfolios, according to Kenneth Lamont, senior research analyst at Morningstar in London.“All of this bodes well for growth in the space in the coming decade,” he said.Here’s a snapshot of some of the biggest funds in the thematic-investing world, plus the latest arrival:Nikko AM ARK Disruptive Innovation FundThe five trends targeted by this fund will converge to create a boom unseen since the second industrial revolution in the late 19th century, according to Renato Leggi, a portfolio manager at ARK Invest. He sees a parallel with history and simultaneous advances in electricity, the telephone and the internal combustion engine.“Companies associated with these platforms should generate more than $50 trillion worth of business value and wealth creation over the next 10 to 15 years,” said Leggi. “If you look at the current value today, these companies are estimated at less than $6 trillion.”One key criteria ARK looks for: The cost decline associated with the technologies should be at a tipping point -- making it affordable to the wider public.CPR Asset Management Global Disruptive Opportunities FundThe mega trends that CPR focuses on include demographic and social changes, globalization, technological revolution and environmental challenges.The firm estimates that by 2050, the world’s population will total 9.7 billion and the number of people aged 60 and older will more than double. This will foment a 50% rise in energy consumption by 2030. It also expects 50% of patients with chronic conditions to rely on virtual health assistants by 2022.Thematic investing “offers higher and sustainable growth opportunities that we want to benefit from over the longer term,” said Estelle Menard, deputy head of global thematic equities at the firm. “It’s storytelling. Once people understand the themes, they are more likely to invest.”CPR AM Silver Age FundCPR’s Silver Age Fund seeks to invest in sectors that benefit from the aging population. The components provide a glimpse at the diversity of thematic funds: Top holdings include digital and pay TV provider Vivendi, anti-aging cream manufacturer L’Oreal, and pharmaceutical giant Roche Holding.Since inception in 2009 it has generated an average annualized return of 11.3%, compared with about 7.8% for the MSCI Europe Index.Pictet Asset Management Global Megatrend SelectFor Hans Peter Portner, head of the thematic equities team at Pictet, the future is being shaped by a series of so-called mega trends. The firm focuses on 14 highlighted by the Copenhagen Institute for Futures Studies, including demographic development, urbanization and globalization.But investors must stay alert: Themes within these trends are constantly evolving.“We launched our fund at the peak of the first wave of investment in clean energy when this technology was not cost-efficient yet,” Portner said. “These assets depreciated quite a lot. We had to re-position the strategy to protect our clients’ investment by going more into energy efficiency.”Since inception in 2008 it has generated an average annualized return of 11.5%, outperforming the MSCI World Index over that period, though it has underperformed on a five-year basis.Lazard AM Global Thematic Focus FundLazard announced their thematic group back in 2003. The latest offering has a broad remit that will see it ride themes like digitization, environmental threats, societal anxieties and more.The fund aims to fully integrate ESG concerns and will be run by the team behind Lazard’s Global Thematic Equity strategy, which the firm says outperformed the MSCI All-Country World Index by over 800 basis points in 2019.To contact the reporter on this story: Anchalee Worrachate in London at aworrachate@bloomberg.netTo contact the editors responsible for this story: Sam Potter at, Cecile Gutscher, Yakob PeterseilFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Calculating The Intrinsic Value Of Teladoc Health, Inc. (NYSE:TDOC)
    Simply Wall St.

    Calculating The Intrinsic Value Of Teladoc Health, Inc. (NYSE:TDOC)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Teladoc Health, Inc...

  • ETF Trends

    Teladoc Takes Flight, Boosting This Disruptive Healthcare ETF

    The J.P. Morgan healthcare conference is underway and the confab often viewed as the super bowl of healthcare meetings is already delivering some notable headlines for investors. The conference effect ...


    Teladoc Health Is Expanding Its Lineup With Deal for InTouch. The Stock Is Taking Off.

    The telemedicine firm’s deal Teladoc Health announced plans to acquire InTouch Health, which sells telehealth software services to hospitals, for $600 million in cash and stock.

  • Teladoc to Buy InTouch Health, Expand Reach in Virtual Care

    Teladoc to Buy InTouch Health, Expand Reach in Virtual Care

    Teladoc (TDOC) to acquire InTouch Health and provide virtual health solutions ranging from critical to everyday care.

  • GlobeNewswire

    Teladoc Health to Acquire InTouch Health

    Teladoc Health, Inc. (TDOC), the global leader in virtual care, today announced it has entered into a definitive agreement to acquire InTouch Health, the leading provider of enterprise telehealth solutions for hospitals and health systems. This acquisition positions Teladoc Health as the partner of choice for health systems seeking a single solution for their entire virtual care strategy, and establishes the company as the only virtual care provider covering the full range of acuity – from critical to chronic to everyday care – through a single solution across all sites of care worldwide.

  • 2020 Predictions to Kick Start the New Year

    2020 Predictions to Kick Start the New Year

    If you've been following Matt McCall for a while, you'll be pleased to know he had a pretty good track record with his 2019 predictions. Amazon (NASDAQ:AMZN) has yet to buy Teladoc (NYSE:TDOC) or a big-box retailer, but ride-hailing companies Uber (NYSE:UBER) and Lyft (NASDAQ:LYFT) did go public … and they did disappoint.Source: InvestorPlace As we continue to count down the days until the ball drops, McCall is ready with his new list of 2020 predictions. In this week's episode of "Moneyline," you'll get a sneak peek of what he believes is in store for the markets.Some of McCall's predictions are perhaps less controversial than others. He believes that 2020 will be the year for biotech stocks, as new therapies and gene editing continue to advance. In terms of new IPOs, he's predicting that just like 2019, 2020 will have some flops. But, it will also have some success stories.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Top-Tier Dividend Stocks for 2020 This year, he warned investors to stay far away from WeWork, which infamously failed to go public. For 2020, he predicts that Airbnb will be the new IPO stock to avoid, thanks to its crazy high valuation and bad customer service. On the flip side, mattress company Casper, backed by the likes of Kylie Jenner and Leonardo DiCaprio, should be a big hit. Make sure to watch it once it prepares to hit the markets.Why does McCall think a mattress company will do so well? For one, he thinks today's mattress retail environment is filled with scams. Customers often walk out with more expensive mattresses and tons of add-ons they didn't want. But beyond that, Sleep Number (NASDAQ:SNBR), the last revolutionary mattress company, has been one of the decade's best-performing stocks. McCall's Podcast But what about the upcoming presidential election? It would be hard to make a list of 2020 predictions without weighing in on that. And perhaps controversially, McCall sees President Donald Trump staying in the White House for another term. But don't get him wrong, that call has nothing to do with his personal politics. It's all about the market.Many investors fear what would happen in the markets following the election of Massachusetts Sen. Elizabeth Warren. She's known for being critical of big pharmaceutical, tech and financial companies. Those are three big sectors, meaning the stakes are high. Because of these fears, McCall believes that voters will come to the polls to re-elect Trump, regardless of other issues.McCall has a few other predictions for "Moneyline" listeners. He believes that a show-stopping name will be added to the collection of Warren Buffett stocks. Could it be a tech company? Or a retailer like Target (NYSE:TGT) or TJX Companies (NYSE:TJX)? Regardless, as Buffett continues to age, McCall thinks it's likely he'll be looking to "cement his legacy" in 2020 with a big move.Tune in to "Moneyline" for more 2020 predictions, his reflections on 2019 and more about new IPOs.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 2019 Losers That Will Be 2020 Winners * 7 Safe Dividend Stocks for Investors to Buy Right Now * 5 Artificial Intelligence Stocks to Consider The post 2020 Predictions to Kick Start the New Year appeared first on InvestorPlace.

  • GlobeNewswire

    Teladoc Health to Participate in Upcoming Investor Conference

    PURCHASE, NY, Dec. 19, 2019 -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Jason Gorevic, chief executive officer, and Mala.

  • Teladoc Stock Is Poised for More Explosive Growth Ahead

    Teladoc Stock Is Poised for More Explosive Growth Ahead

    Teladoc Health (NYSE:TDOC) continued rewarding investors with the stock uptrend in the last quarter. And for good reason, too. The company posted strong third-quarter top-line results and raised its guidance. Markets view the multinational telemedicine and virtual healthcare supplier as both part healthcare and part technology. By utilizing artificial intelligence and analytics and licensing its platform services, this scalable company touched all-time highs recently. The stock may forge new highs if it raises its guidance yet again.Source: Piotr Swat / In the third quarter, Teladoc reported revenue of $138 million, up 24% from last year. Revenue growth was lifted by global subscription access fees of $119.1 million. This accounted for 86% of its total revenue. It lost 28 cents a share, which is not a concern because the company is building its sales levels and taking market share first. The company forecast Q4 revenue in the range between $149 million and $153 million.For full-year 2019, revenue will be $546 million to $550 million. This is up from its previous guidance of $538 million to $545 million. Teladoc expects total visits topping up to 4.1 million.InvestorPlace - Stock Market News, Stock Advice & Trading TipsVisits rose 45% from last year to 928,000. And utilization rates came in just under 8%, up 17 basis points year-over-year. Strong TailwindsTeladoc benefited from the greatest population expansion in the company's history. When over 17 million people gained access to Teladoc, it lifted total visits and revenue. More importantly, TDOC stock rose because investors expect the company to further entrench its distribution channels. Management added UnitedHealth (NYSE:UNH) to its platform. That netted 15 million commercial members and gives UNH a fully integrated virtual care offering to its customers. * 5 Large-Cap Dividend Stocks to Buy Teladoc proved it can deliver on a product rollout without any project delays. Its initial launch went through without any issues. The teams at Teladoc and UNH proved they can collaborate successfully. This may lead to more collaborative projects for Teladoc in the future, further expanding its population expansion.In the last quarter, the company saw request for proposal volumes jump 25% year-over-year. This implies product orders will continue increasing as client interest strengthens. Bookings rose around 30% and along with deal sizes increasing, Teladoc is on a positive trajectory. Global GrowthTeladoc launched in the United Kingdom and introduced the market to its first virtual mental health service. It counted on American International Group (NYSE:AIG) for the launch. In Canada, Great-West Life added the Mental Health Navigator service. In the U.S., companies like UPS (NYSE:UPS) and Nationwide Insurance chose Teladoc to give over 100,000 employees access to medical experts. So, the Teladoc medical expert service, which is a virtual center of excellence, should improve health support for those who need it.2020 will benefit from accelerating revenue growth, as management forecasts long-term annual revenue growth between 20% and 30%. And thanks to the customer base getting bigger annually and clients coming from a variety of global locations, TDOC stock deserves richer premiums. Price Target And My TakeawayNine of the 14 analysts who cover Teladoc stock rank it as a "buy." Their average price target is $85.07. Conversely, the cautious investor may forecast a downside scenario in which revenue growth stalls. Assume that the perpetuity growth rate is 4% and revenue growth falls to 30% annually. In this case, TDOC stock is worth $70.For now, Teladoc investors need not expect growth slowing. The company is gaining momentum and winning bigger contract deals. This will support its historical sales growth rates, sending the stock higher.As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Large-Cap Dividend Stocks to Buy * 3 of the Worst ETFs in 2019 * 7 Biotech Stocks to Buy and Hold in 2020 The post Teladoc Stock Is Poised for More Explosive Growth Ahead appeared first on InvestorPlace.

  • CEO: Why telehealth can 'upend' health care like Amazon did retail
    Yahoo Finance

    CEO: Why telehealth can 'upend' health care like Amazon did retail

    The fusion of video technology and medical diagnoses carries the promise of disrupting health care at lower cost, according to American Well co-CEO and president Roy Schoenberg.

  • Is Teladoc Inc (TDOC) A Good Stock To Buy?
    Insider Monkey

    Is Teladoc Inc (TDOC) A Good Stock To Buy?

    The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]

  • 3 Small-Cap Stocks with Big-Time Upside Potential

    3 Small-Cap Stocks with Big-Time Upside Potential

    It’s hard for the little guys to get noticed sometimes, but often, it’s the little guys that are worth watching. Naturally, this applies to investing, too.Much has been said already about the record-breaking year for the S&P 500. As we reached the final month of the decade, after such a sustained rally, it is getting harder and harder to find true bargains. The top analysts, though, know that further down the market cap ladder, unseen by the casual observer, is where some of the true gems reside, the ones from which investors stand to reap substantial rewards.So, we took out our virtual bargain detector, opened TipRanks’ Stock Screener and looked for 3 stocks with smaller market caps poised for growth, specifically ones the analysts think are set for gains in the months ahead. Let’s take a closer look.International Money Express (IMXI)Remittances are making an increasingly large impact on the economies of many countries, playing a part in their economic growth, and in people’s livelihoods. Overall global remittance is expected to grow 3.7% to $715 billion in 2019. This includes $549 billion to developing nations.One company hoping to get a slice of the growing industry is International Money Express. The Miami based company provides remittance services for select Latin American markets, with strongholds in the two biggest markets - it is the market leader in Guatemala, and the second largest provider in Mexico.Additionally, IMXI has set its sights on new territories, both in Latin America and Africa, as well as expanding in the US and Canada. The company favors a differentiated agent acquisition strategy of handpicking agents with which the local migrant population has a cultural or linguistic affinity over increasing the number of agent locations.Cowen’s George Mihalos thinks the game plan is working well. The 5-star analyst noted, “We believe IMXI deserves a premium valuation relative to its money remittance peers given its superior growth profile and differentiated business model [..] We see IMXI leveraging its differentiated agent strategy to further capture market share in the Latin American remittance corridor, driving sustainable low-mid teens revenue growth. With the shares trading at a discount to slower growing peers such as WU, we see an opportunity for multiple expansion near term.”To this end, Mihalos initiated coverage on IMX stock with an Outperform rating, along with a price target of $17. This conveys the 5-star analyst’s confidence in IMXI’s ability to climb 32% higher in the next 12 months. (To watch Mihalos’ track record, click here)Where does the rest of the Street side on this digital payments platform? It appears mostly bullish, as TipRanks analytics demonstrate IMXI as a Strong Buy. Out of 5 analysts tracked by TipRanks in the last 3 months, 4 are bullish on the stock while 1 remains sidelined. With a return potential of nearly 36%, the stock’s consensus target price stands at $17.50 (See IMXI stock analysis on TipRanks)Exicure (XCUR)With a market cap of $219.6 million, Exicure is the smallest company on our list. The micro-cap biotech focuses on developing drugs for neurology, oncology, and dermatology.Exicure’s unique selling point (USP) is its proprietary spherical nucleic acid (SNA) technology, which can better the delivery and efficiency of current nucleic acid-based therapies. The company is expected to announce its first SNA based neurology candidate before year’s end, and it has indicated it will be a rare indication for which there are few available therapies. In addition, Exicure also recently announced an agreement with Allergan to develop treatments for hair disorders, also based on Exicure’s SNA technology.The pioneering biotech has excited Guggenheim’s Yatin Suneja, who wrote, “We expect XCUR’s SNA platform to attract interest from biopharma companies. We believe that nucleic acid therapeutics are a growing class of products, and the highly adaptive SNA technology could potentially improve the delivery and efficiency of multiple compounds. Therefore, we expect strong interest (as highlighted by a recent collaboration with Allergan) from various biopharma players in partnering with XCUR to leverage this technology.”As a result, Suneja thinks the stock, currently at $2.89, will soon be worth $9.00 a share, and recommends buying it. We are talking about over 200% upside here. (To watch Suneja’s track record, click here)Suneja’s bullish call resonates with the Street. Although only 3 analysts have weighed in with a view on Exicure over the last 3 months, all have rated the biotech pioneer as a Buy, making the Street consensus a Strong Buy. The average target stands at $7.33, below Suneja’s target, but still providing ample upside of 154%. (See Exicure stock analysis on TipRanks)Teladoc (TDOC)The advent of the smartphone has changed the way we interact with the world in every possible way, from shopping, to how we get around, to how we consume culture, amongst many other novelties. One industry going through a smart technological transformation right now is the health industry, with the rise of the telehealth space disrupting traditional doctor-patient conventions.RBC’s Sean Dodge thinks Teledoc is ‘virtually unstoppable,’ noting, “Virtual health is going mainstream. Awareness and comfort with the technology is reaching a tipping point and the breadth of potential use-cases is expanding rapidly. There are more examples of this surfacing across healthcare every day. We are also seeing increasing evidence Virtual First benefit design is beginning to take hold, which adds even more momentum to our outlook. While the rising tide will lift all boats, we believe Teladoc is the best positioned to capitalize on this. It's superior consumer engagement platform, breadth of offerings/clinical capabilities and global reach are all important and durable competitive differentiators. The combination of new member adds, cross-selling and ramping utilization should continue to drive 25%+ organic revenue growth for the next 3+ years..”On the back of the glowing assessment, Dodge initiated coverage on Teladoc stock, with an Outperform rating. The analyst suggests that if everything goes as planned, TDOC will be a $100 stock in the next 12 months, implying nearly 28% return. (To watch Dodge’s track record, click here)To find other good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Teladoc Adds to its Services With Tailored Nutrition Plans

    Teladoc Adds to its Services With Tailored Nutrition Plans

    Teladoc (TDOC) enhances its service portfolio with the addition of personalized diet programs.

  • GlobeNewswire

    Teladoc Health Expands Services with Personalized Nutrition Counseling

    Teladoc Health, Inc. (TDOC) today announced the continued expansion of its clinical services with the addition of Teladoc Nutrition, personalized nutrition counseling combined with specialized care from a registered dietitian. Providing virtual access to nutrition services as part of the Teladoc Health comprehensive continuum of care will further optimize long-term health outcomes and ultimately reduce overall medical costs, particularly for those individuals with existing chronic and complicated health conditions.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 2, 2019: EVFM, AQMS, ROKU, TDOC, COUP

    Benzinga Pro's Stocks To Watch For Monday Evofem Biosciences (EVFM)  - Announced its AMPREVENCE study met the primary and secondary endpoints of “reducing the risk of chlamydia and gonorrhea infection, ...

  • Teladoc (TDOC) Up 73% Year to Date: Will the Rally Continue?

    Teladoc (TDOC) Up 73% Year to Date: Will the Rally Continue?

    Teladoc's (TDOC) presence in the growing telehealth industry with many deal wins and international expansion is likely to drive long-term growth.

  • Investopedia

    Stocks Break Higher, and Small Caps Lead the Charge

    Market indexes jumped higher early in the session and didn't give back their gains to end the day. While the S&P 500 (SPX), Nasdaq 100 (NDX), and Dow Jones Industrial (DJX) indexes all surged higher, it was the small- and micro-cap indexes that showed the most dramatic movements by far. The chart below shows how iShares' index-tracking ETFs for both the Russell 2000 (IWM) and the Russell Microcap (IWC) closed over 2% higher and posted their highest close in the past six months.

  • Is Teladoc Health (TDOC) Stock Outpacing Its Medical Peers This Year?

    Is Teladoc Health (TDOC) Stock Outpacing Its Medical Peers This Year?

    Is (TDOC) Outperforming Other Medical Stocks This Year?

  • PR Newswire

    MinuteClinic Launches Video Visit Offering in Illinois

    WOONSOCKET, R.I., Nov. 19, 2019 /PRNewswire/ -- CVS Health (CVS) today announced that MinuteClinic, the company's retail medical clinic, has rolled out its video visit offering in the state of Illinois. People in Illinois with minor illnesses, minor injuries and skin conditions can now seek care through MinuteClinic Video Visits, a telehealth offering.

  • PR Newswire

    MinuteClinic Launches Video Visit Offering in New Jersey

    WOONSOCKET, R.I., Nov. 19, 2019 /PRNewswire/ -- CVS Health (CVS) today announced that MinuteClinic, the company's retail medical clinic, has rolled out its video visit offering in the state of New Jersey. People in New Jersey with minor illnesses, minor injuries and skin conditions can now seek care through MinuteClinic Video Visits, a telehealth offering.